IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients with Sickle Cell Anemia and Recurrent Vaso-occlusive Pain
S
Seethal Jacob, MD
Primary Investigator
Overview
In this research study, we want to learn more about treatment of sickle cell anemia (SCA). Imatinib is a medication that is commonly used to treat certain types of cancers. Imatinib has not been approved to treat SCA or any pain associated with anemia and is considered an investigational treatment (i.e. not approved by the FDA) for this research study.
Description
Participants who join as a normal donor for this study will be asked to provide blood samples up to 5 times in a 7-month period. This blood will be drawn from the arm using an IV needle. This needle will be removed after blood is collected.
Participants who receive treatment will come to Riley Hospital for Children Outpatient Center 7 times over the next 7 months and take an oral dose of imanitib every day for the next 6 months. Visits will include: review of medical history; physical exam with vital signs; height and weight measurement; EKG; echocardiogram; blood tests; review of study pain journal; urine pregnancy test (for women of childbearing potential).
Participants who are taking part in treatment will receive a $50 gift card for each monthly visit after the initial baseline visit.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Sickle Cell Anemia,Sickle Cell Disease
-
Age: Between 18 Years - 30 Years
-
Gender: All
Individuals between 18 and 30 years of age with a documented diagnosis of sickle cell anemia and at least 2 documented episodes of vaso-occlusive pain in the prior year.
Women who are pregnant or breastfeeding will not be eligible.
Additional Information:
Updated on
09 Mar 2024.
Study ID: 1905035827
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact